Posted on 12 May 2011
Tags: big pharma, opportunities, shire
The UK's Shire has been making a series of small-$3 million to $5 million-investments in stem cell developers as the CEO continues to hunt for viable new business opportunities.
Read the report Shire's acquisition plans at Reuters
Click here to cancel reply.
Email (will not be published) (required)
Your website (optional)
© 2020 Wildwood Ventures Ltd.